Parathyroid carcinoma as a challenging diagnosis: Report of three cases

被引:9
作者
Campenni, Alfredo [1 ]
Ruggeri, Rosaria Maddalena [2 ]
Sindoni, Alessandro [1 ]
Giovinazzo, Salvatore [2 ]
Calbo, Letterio [3 ]
Ieni, Antonio
Monaco, Maurizio [4 ]
Tuccari, Giovanni
Benvenga, Salvatore [2 ,5 ]
Baldari, Sergio [1 ]
机构
[1] Univ Messina, Nucl Med Unit, Dept Radiol Sci, Messina, Italy
[2] Univ Messina, Endocrinol Sect, Dept Clin & Expt Med & Pharmacol, Messina, Italy
[3] Univ Messina, Sect Surg, Dept Human Pathol, Messina, Italy
[4] Univ Messina, Cardiovasc & Thorac Dept, Messina, Italy
[5] AOU Policlin G Martino, Program Mol & Clin Endocrinol & Womens Hlth, Messina, Italy
来源
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM | 2012年 / 11卷 / 03期
关键词
AgNOR; Hypercalcemia; Ki-67; Parathyroid carcinoma; Primary hyperparathyroidism; MANAGEMENT; ADENOMAS; CANCER; KI-67; RETINOBLASTOMA; HYPERCALCEMIA; HYPERPLASIAS; PITFALLS; GLANDS;
D O I
10.14310/horm.2002.1367
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Parathyroid carcinoma (PC) is a rare malignancy with an indolent but progressive course. This rare tumour is often difficult to diagnose preoperatively, thus limiting the efficacy of surgery. As long-term survival is largely dependent on the extent of the primary surgical resection, it is of great importance to consider PC in the differential diagnosis of hyperparathyroidism. We herein report three PC patients with different clinical histories who were followed up at our hospital for over a 5-year period, emphasizing the variability in clinical presentation of this rare tumour. Moreover, NORA (Nucleolar Organizer Regions, a standardised silver-stain, marker of proliferation rate) values encountered in these PC patients confirm that AgNOR analysis may be regarded as an additional tool when the pathologist encounters difficulties in defining parathyroid lesions which are not clearly benign.
引用
收藏
页码:368 / 376
页数:9
相关论文
共 33 条
[21]   DIAGNOSIS AND TREATMENT OF PATIENTS WITH PARATHYROID CARCINOMA - AN UPDATE AND REVIEW [J].
OBARA, T ;
FUJIMOTO, Y .
WORLD JOURNAL OF SURGERY, 1991, 15 (06) :738-744
[22]  
Obara T, 1997, SEMIN SURG ONCOL, V13, P134, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<134::AID-SSU9>3.0.CO
[23]  
2-A
[24]   CLINICAL COURSE OF METASTATIC PARATHYROID CANCER [J].
SANDELIN, K ;
TULLGREN, O ;
FARNEBO, LO .
WORLD JOURNAL OF SURGERY, 1994, 18 (04) :594-599
[25]  
SCHANTZ A, 1973, CANCER-AM CANCER SOC, V31, P600, DOI 10.1002/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO
[26]  
2-0
[27]   Intrathyroidal parathyroid carcinoma presenting with only hypercalcemia [J].
Schmidt, JL ;
Perry, RC ;
Philippsen, LP ;
Wu, HH .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2002, 127 (04) :352-353
[28]   Parathyroid carcinoma [J].
Shane, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (02) :485-493
[29]   Clinical Presentation, Staging and Long-Term Evolution of Parathyroid Cancer [J].
Talat, Nadia ;
Schulte, Klaus-Martin .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (08) :2156-2174
[30]   AgNOR quantity as a prognostic tool in hyperplastic and neoplastic parathyroid glands [J].
Tuccari, G ;
Abbona, G ;
Giuffrè, G ;
Papotti, M ;
Gasparri, G ;
Barresi, G ;
Bussolati, G .
VIRCHOWS ARCHIV, 2000, 437 (03) :298-303